Company intelligence / Profile preview

ActiveSignal

United States

Ownership: Private
Development stage: Other

Overview

ActivSignal is developing an early detection assay for pancreatic cancer using a platform that identifies multi-target bio-signatures in patient samples[1]. The company focuses on profiling proteins and other non-DNA biomarkers to provide a highly specific and sensitive platform for early cancer detection[1].

Therapeutic areas: Oncology
Modalities: Diagnostic assay (protein profiling platform)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on ActiveSignal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ActiveSignal.

Explore the full profile